Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-17.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4
Industry P/E
--
EV/EBITDA
-0.8
Div. Yield
0 %
Debt to Equity
-1.1
Book Value
$--
EPS
$-12.4
Face value
--
Shares outstanding
6,056,050
CFO
$-483.41 Mln
EBITDA
$-573.68 Mln
Net Profit
$-598.44 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
| -71.1 | 19.3 | -24.1 | -91.9 | -78.1 | -71.1 | -- |
|
BSE Sensex
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
| -87.1 | -86.3 | 5.7 | -56.0 | 216.2 | 278.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
|
1.7 | 10.2 | 1.9 | -40.1 | -1,541.0 | -- | -- | 4.0 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.7 | 3.9 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.7 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.6 | |
| 25.4 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 |
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United... States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Address: 555 Long Wharf Drive, New Haven, CT, United States, 06511 Read more
Founder, CEO, President, & Director
Dr. Vimal D. Mehta Ph.D.
Founder, CEO, President, & Director
Dr. Vimal D. Mehta Ph.D.
Headquarters
New Haven, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BioXcel Therapeutics Inc (BTAI) stood at $ 64 Mln as on 31-Mar-25
The share price of BioXcel Therapeutics Inc (BTAI) is $1.73 (NASDAQ) as of 18-Jun-2025 16:00 EDT. BioXcel Therapeutics Inc (BTAI) has given a return of -78.13% in the last 3 years.
BioXcel Therapeutics Inc (BTAI) has a market capitalisation of $ 10 Mln as on 17-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of BioXcel Therapeutics Inc (BTAI) is 3.97 times as on 17-Jun-2025, a 44% premium to its peers’ median range of 2.75 times.
Since, TTM earnings of BioXcel Therapeutics Inc (BTAI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioXcel Therapeutics Inc (BTAI) and enter the required number of quantities and click on buy to purchase the shares of BioXcel Therapeutics Inc (BTAI).
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Address: 555 Long Wharf Drive, New Haven, CT, United States, 06511
The CEO & director of Dr. Vimal D. Mehta Ph.D.. is BioXcel Therapeutics Inc (BTAI), and CFO & Sr. VP is Dr. Vimal D. Mehta Ph.D..
There is no promoter pledging in BioXcel Therapeutics Inc (BTAI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| BioXcel Therapeutics Inc. (BTAI) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-1541.04
|
|
Net Margin(%)
|
-2163.17
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioXcel Therapeutics Inc (BTAI) was $0 Mln.
$0.09
(
